Adaptive design improvements in the continual reassessment method for phase I studies.
The continual reassessment method (CRM) enables full and efficient use of all data and prior information available in a phase I study. However, despite a number of recent enhancements to the method, its acceptance in actual clinical practice has been hampered by several practical difficulties. In this paper, we consider several further refinements in the context of phase I oncology trials. In particular, we allow the trial to stop when the width of the posterior 95 per cent probability interval for the maximum tolerated dose (MTD) becomes sufficiently narrow (that is, when the information accumulating from the trial data reaches a prespecified level). We employ a simulation study to evaluate five such stopping rules under three alternative states of prior knowledge regarding the MTD (accurate, too low and too high). Our results suggest our adaptive designs preserve the CRM's estimation ability while offering the possibility of earlier stopping of the trial.
Medtronic Inc., Minneapolis, Minnesota 55421, USA.
J M
JM
Heyd
B P
BP
Carlin
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001499:Bayes Theorem; D017321:Clinical Trials, Phase I as Topic / Q000706:statistics & numerical data*; D003198:Computer Simulation; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016015:Logistic Models; D008495:Medical Oncology / Q000706:statistics & numerical data; D009010:Monte Carlo Method; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents